Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Medtronic
Moodys
Johnson and Johnson
Colorcon

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

CEFTRIAXONE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Ceftriaxone, and when can generic versions of Ceftriaxone launch?

Ceftriaxone is a drug marketed by Acs Dobfar, Agila Speclts, Aurobindo Pharma Ltd, Bedford, Facta Farma, Fresenius Kabi Usa, Hospira Inc, Lupin, Qilu, Samson Medcl, Sandoz, Sandoz Inc, Teva, Wockhardt, Akorn Inc, Astral, Cephazone Pharma, Hikma Farmaceutica, Teva Pharms Usa, B Braun, Baxter Hlthcare, and Hikma. and is included in thirty-six NDAs.

The generic ingredient in CEFTRIAXONE is ceftriaxone sodium. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ceftriaxone sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Ceftriaxone

A generic version of CEFTRIAXONE was approved as ceftriaxone sodium by ASTRAL on January 20th, 2017.

  Start Trial

Drug patent expirations by year for CEFTRIAXONE
Drug Prices for CEFTRIAXONE

See drug prices for CEFTRIAXONE

Recent Clinical Trials for CEFTRIAXONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme (Australia) Pty LimitedPhase 3
The University of QueenslandPhase 3
Centre Hospitalier Universitaire de la RéunionPhase 4

See all CEFTRIAXONE clinical trials

Pharmacology for CEFTRIAXONE

US Patents and Regulatory Information for CEFTRIAXONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa CEFTRIAXONE ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 065227-004 Mar 15, 2007 DISCN No No   Start Trial   Start Trial   Start Trial
Cephazone Pharma CEFTRIAXONE ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 065294-001 Mar 26, 2007 DISCN No No   Start Trial   Start Trial   Start Trial
Aurobindo Pharma Ltd CEFTRIAXONE ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 065505-004 Jul 31, 2008 DISCN No No   Start Trial   Start Trial   Start Trial
Hikma Farmaceutica CEFTRIAXONE ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 065342-003 Jan 10, 2008 AP RX No No   Start Trial   Start Trial   Start Trial
Lupin CEFTRIAXONE ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 065125-002 Sep 30, 2003 AP RX No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa CEFTRIAXONE ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 065245-003 Feb 15, 2006 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Medtronic
Moodys
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.